1. Franciosa JA, Park M: Lack of correlation between exercise capacity and indices of resting left ventricular performance in heart failure. Am J Cardiol47:33-39, 1981.
2.
2. McCullough PA, Philbin EF, Spertus JA, et al: Conformation of a heart failure epidemic: Findings from the Resource Utilization Among Congestive Heart failure (REACH) study. J Am Coll Card39:60-69, 2002.
3.
3. Goldberg RJ, Samad NA,Yarzebski J, et al: Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med340:1162-1168, 1999.
4.
4. Holmes DR, Bates ER, Kleiman NS, et al: Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. J Am Coll Card26:668-674, 1995.
5.
5. Holmes DR, Berger PB, Hochman JS: Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation100:2067-2073, 1999.
6.
6. Goldberg RJ, Gore JM, Thompson CA, et al: Recent magnitude of and temporal trends (1994-1997) in the incidence and hospital rates of cardiogenic shock complicating acute myocardial infarction: The second National Registry of Myocardial Infarction. Am Heart J141:65-72, 2001.
7.
7. Goldman L: Assessment of perioperative cardiac risk [editorial comment]. N Engl J Med330:770-770, 1994.
8.
8. Charlson ME, MacKenzie CR, Gold JP, et al: Risk for postoperative congestive heart failure. Surg Gynecol Obstet172:95-104, 1991.
9.
9. Pedersen T, Eliasen K, Hendriksen E: A prospective study of risk factors and cardiopulmonary complications associated with anesthesia and surgery: Risk indicators of cardiopulmonary morbidity. Acta Anesthesiol Scand34:144-155, 1990.
10.
10. Goldman L, Caldera DL, Nussbaum SR, et al: Multifactorial index of cardiac risk in non-cardiac surgical procedures. N Engl J Med297:845-845, 1977.
11.
11. Lee TH, Marcantonio ER, Mangione CM, et al: Derivation and prospective validation of a simple index for prediction of cardiac risk of major non-cardiac surgery. Circulation100:1043-1049, 1999.
12.
12. Eagle KA, et al: ACC/AHA guideline update for perioperative cardiovascular evaluation for non-cardiac surgery. J Am Coll Card39:542-553, 2002.
13.
13. Polanczyk CA, Marcantonio ER, Goldman L, et al: Impact of age on perioperative complications and length of stay in patients undergoing non cardiac surgery. Ann Intern Med134:637-643, 2001.
14.
14. Nashef SA, Roques F, Michel P, et al: Coronary surgery in Europe comparison of the national subsets of the European system for cardiac operative risk evaluation database. Eur J Cardiothor Surg17:396-399, 2000.
15.
15. Estafanous FG, Loop FD, Higgins TL, et al: Increased risk and decreased morbidity of coronary artery bypass grafting between 1986 and 1994. Ann Thorac Surg65:383-389, 1988.
16.
16. Katz NM, Wolfe-Pearce JL, Chase GA: Comparison of results and risk factors of cardiac surgery in two 3-year time periods in the 1990s. Am J Cardiol81:1400-1404, 1998.
17.
17. Fao V, lvanov J, Weisel RD, et al: Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg112:38-51, 1996.
18.
18. Yau TM, Fedak PW, Weisel RD, et al: Predictors of operative risk for coronary bypass operations in patients with left ventricular dysfunction. J Thorac Cardiovasc Surg118:1006-1013, 1999.
19.
19. Yau TM, Borger MA, Weisel RD, et al: The changing pattern of reoperative coronary surgery: Trends in 1230 consecutive reoperations. J Thorac Cardiovasc Surg120:156-163, 2000.
20.
20. Yamamuro M, Lytle BW, Sapp SK, et al: Risk factors and outcomes after coronary reoperation in 739 elderly patients. Ann Thorac Surg70:516-526, 2000.
21.
21. Breisblatt WM, Stein KL, Wolfe CJ, et al: Acute myocardial dysfunction and recovery: A common occurrence after coronary bypass surgery. J Am Coll Card15:1261-1269, 1990.
22.
22. Chang PR, Sussman MS, Conte JV, et al: Postoperative ventricular function and cardiac enzymes after on-pump versus off-pump CABG surgery. Am J Cardiol89:1107-1110, 2002.
23.
23. Butterworth JF, Legault C, Royster RL, et al: Factors that predict the use of positive inotropic drug support after cardiac valve surgery. Anesth Analg86:461-467, 1998.
24.
24. Poole-Wilson PA: Treatment of acute heart failure: Out with the old, in with the new. JAMA287:1578-1580, 2002.
25.
25. Bellomo R, Chapman M, Finfer S, et al: Low-dose dopamine in patients with early renal dysfunction: A placebo controlled randomized trial. Lancet356:2139-2143, 2000.
26.
26. Remme WJ: Positive inotropes: A new horizon or still a dead end?Cardiovasc Drugs Ther15:375-377, 2001.
27.
27. Fowler MB, Alderman EL, Oesterlee SN, et al: Greater augmentation of myocardial blood flow with dobutamine. Circulation70(suppl):103-111, 1984.
28.
28. Neuean J, Smitz W: Increase in myocardial Gi proteins in heart failure. Lancet2:936-937, 1988.
29.
29. Ferguson TB, Coombs LR, Peterson ED, et al: Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA287:2221-2227, 2002.
30.
30. Poldermans D, Boersma E, Bax JJ, et al: The effect of bisoprolol on perioperative mortality and myocardial infarction in high risk patients undergoing vascular surgery. N Engl J Med335:1761-1767, 1999.
31.
31. Tarnow J, Komar K: Altered hemodynamic response to dobutamine in relation to the degree of preoperative betablockade. Anesthesiology68:912-919, 1988.
32.
32. Boldt J, Kling D, Zickman D, et al: Haemodynamic effects of the phophodiesterase inhibitor enoximone in comparison with dobutamine in esmolol-treated cardiac surgery patients. Br J Anaesth64:611-616, 1990.
33.
33. Lowes BD, Tsvetkova T, Eichhorn EJ, et al: Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol81:141-149, 2001.
34.
34. Gregorini L, Marco J, Kozakova M, et al: Alpha adrenergic blockade improves recovery of myocardial perfusion and function after coronary stunting in patients with acute myocardial infarction. Circulation99:482-490, 1999.
35.
35. Shan K, Bick RJ, Poindexter BJ, et al: Altered adrenergic receptor density in myocardial hibernation in humans: A possible mechanism of depressed myocardial function. Circulation102:2599-2606, 2000.
36.
36. Baim DS: Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow. Am J Cardiol73:111, 168-173, 1989.
37.
37. Baruch L, Patacsil R, Hameed A, et al: Pharmacodynamic effects of milrinone with and without a bolus loading infusion. Am Heart J141:266-273, 2001.
38.
38. Bohm M, Morano L, Pieske B, et al: Contribution of CAMP phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res68:689-701, 1991.
39.
39. Cuffe MS, Califf RM, Adams KF, et al: Short-term intravenous milrinone for acute exacerbation of chronic heart failure. JAMA287:1541-1547, 2002.
40.
40. Bohm M, Deutsch HJ, Hartmann D, et al: Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol30:992-996, 1997.
41.
41. Kikura M, Sato S: The efficacy of preemptive milrinone or amrinone therapy in patients undergoing coronary artery bypass grafting. Anesth Analg94(1):22-30, 2002.
42.
42. Janelle GM, Urdaneta F, Bias ML, et al: Inhibition of phosphodiesterase type 111 before aortic cross-clamping reserves intramyocardial cyclic adenosine rnonophosphate during cardiopulmonary bypass. Anesth Analg92:1377-1383, 2001.
43.
43. Gage J, Ruthman H, Lucido D, et al: Additive effects of dobutamjne and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation74:367-373, 1986.
44.
44. Kunimoto F, Isa Y, Ohki S, et al: Comparison of the hemodynamic effects of amrinone in patients who required lowto-moderate-dose and high-dose catecholamines after cardiac valve replacement. Crit Care Med27:2698-2702, 1999.
45.
45. Hasenfuss G, Pteske B, Castell M, et al: Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation98:2141-2147, 1998.
46.
46. Endoh M: Mechanism of action of calcium sensitizers-update 2001. Cardiovasc Drug Ther15:397-403, 2001.
47.
47. Lilleberg J, Nieminen MS, Akkila J: Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J19:660-668, 1998.
48.
48. Nieminen MS, Akkila J, Hasenfuss G, et al: Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patientswith congestive heart failure. J Am Coll Cardiol36:1903-1912, 2000.
49.
49. Follath F, Cleland JG, Just H, et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) a randomized double blind trial. Lancet360:196-202, 2002.
